Opendata, web and dolomites

TK-NEO SIGNED

Personalized Cancer Immunotherapy through DNA-EP vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TK-NEO project word cloud

Explore the words cloud of the TK-NEO project. It provides you a very rough idea of what is the project "TK-NEO" about.

protecting    relapse    cancer    neo    disease    patented    heterogeneous    vaccination    patients    immune    market    final    licensing    feasibility    confirm    alternative    melanoma    mice    lung    reduce    financing    boosting    company    chemotherapeutic    maintenance    anti    gmp    constituted    tumours    tumor    clinical    client    5m    vc    metastatic    vaccine    dna    stage    validate    treatment    takis    medicine    efficacy    rna    tk    ip    combining    neoantigen    customized    validation    applicability    investment    co    human    proven    week    underwent    sequencing    pharma    ncv    respect    solution    solid    patient    surgery    license    completion    first    manufacturing    humanized    therapeutic    immunity    safety    zero    right    precision    synthesis    release    tumors    days    exclusive    fold    tests    total    instrument    perfect    mou    ncvs    sequence    carry    form    sme    additional    tumour    electroporation    locally    authorization    trials    pricing    ep    strategy   

Project "TK-NEO" data sheet

The following table provides information about the project.

Coordinator
TAKIS SRL 

Organization address
address: VIA DI CASTEL ROMANO 100
city: ROMA
postcode: 128
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TAKIS SRL IT (ROMA) coordinator 50˙000.00

Map

 Project objective

TK-NEO is a DNA-based Neoantigen Cancer Vaccine (NCV), for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours. NCVs are a new form of precision medicine and are a perfect clinical approach for highly heterogeneous tumors in patients with metastatic disease. Takis has developed and patented a unique method for production of patient-specific NCVs based on a 6-week process, from sequencing the specific tumour DNA, synthesis of the right DNA sequence for the specific tumour, delivery through a specific Electroporation (EP) technology used under exclusive license. The solution was proven at pre-clinical stage to reduce to zero a human lung cancer in humanized mice in 60 days and to increase the efficacy several fold with respect to alternative RNA and DNA based NCVs in protecting relapse and boosting immune responses as required for the maintenance of long-term anti-tumor immunity. The strategy to reach the market for TK-NEO is to license the IP of TK-NEO to a large pharma company, after completion of clinical validation trials to demonstrate the applicability and safety of the approach: phase I clinical trials in melanoma are targeted during SME Instrument project, while implementation of a GMP manufacturing to carry out phase II clinical trials and the implementation of the trials will require additional 5M investment. The Total Available Market is constituted by melanoma patients who underwent surgery and first chemotherapeutic treatment, who are estimated in the order of 30.000 patients per year combining EU and US. The objectives of the feasibility study are: 1) to validate the feasibility and the authorization process for the release tests, 2) to confirm investment, cost and pricing for TK-NEO, 3) to define a MoU with VC or with the final client (pharma) for the co-financing of the clinical development of customized TK-NEO and for future licensing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TK-NEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TK-NEO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More